Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous cold-stored platelets are a cellular therapy product derived from a patient's own blood and stored at refrigerated temperatures (typically 1°C to 6°C). Unlike standard room-temperature platelets (20°C to 24°C), cold storage preserves platelets in a "primed" or pre-activated state. This storage condition helps maintain high levels of surface receptors, such as the glycoprotein Ib-IX-V complex, and promotes the exposure of procoagulant phospholipids like phosphatidylserine on the cell surface. These changes result in enhanced adhesion to damaged vascular endothelium and accelerated thrombin generation upon re-infusion. The primary therapeutic goal is to provide rapid hemostasis in perioperative settings, particularly in cardiac surgery, while eliminating the risks associated with allogeneic transfusions, such as transfusion-transmitted infections and transfusion-related acute lung injury (TRALI).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous cold-stored platelets.